Literature DB >> 30301632

Identification of a Patient Acceptable Symptomatic State Score for the International Hip Outcome Tool in People Undergoing Hip Arthroscopy.

Samuel Maxwell1, Nicholas Pergaminelis2, Jesse Renouf2, Oren Tirosh3, Phong Tran2.   

Abstract

PURPOSE: To determine a Patient Acceptable Symptomatic State (PASS) score for the 33-item International Hip Outcome Tool (iHOT-33) in people undergoing hip arthroscopy for primary diagnoses of femoroacetabular impingement syndrome, acetabular labral tears, and/or ligamentum teres pathology.
METHODS: Consecutive participants underwent hip arthroscopy by a single surgeon between August 2011 and May 2016. Participants were included if they were between ages 18 and 60 years and underwent hip arthroscopy for femoroacetabular impingement syndrome, acetabular labral tears, or ligamentum teres pathology. Participants were excluded if they did not speak sufficient English to complete the iHOT-33, had evidence of hip dysplasia, had less than 2 mm of joint space on anteroposterior radiograph, or underwent subsequent total hip replacement surgery. Participants completed the iHOT-33 preoperatively and at a minimum of 1 to a maximum of 5 years postoperatively. Participants were also asked to answer yes or no to the external anchor question of "Taking into account all the activities you do during your daily life, your level of pain and also your functional impairment, are you satisfied with your current state following your surgery?" A receiver operating characteristic (ROC) curve was used to identify the PASS score. Multiple logistic regression was performed to determine if patient factors, primary preoperative diagnosis, or intraoperative findings predicted achievement of the PASS score.
RESULTS: A total of 117 participants undergoing hip arthroscopy were included: 72 women (61.1%) and 45 men (38.5%) with mean age of 36.81 years (18-59). Forty-two (35.9%) had cam morphology, 18 (15.4%) had pincer morphology, 78 (67.2%) had labral tears, and 97 (82.9%) had ligamentum teres tears. Mean time to final follow-up was 2.25 years (range, 1-5). The PASS score at a mean of 2.25 years postoperatively was 58 as determined by the cutoff threshold on the ROC curve with the lowest difference between sensitivity and specificity (area under the ROC curve 0.88; P < .01; 95% confidence interval [CI], 0.81-0.95). No factors were predictors of achievement of the PASS score in this study (P > .05), including age (odds ratio [OR], 0.71; 95% CI, 0.32-1.56), sex (OR, 1.02; 95%, CI 0.98-1.06), preoperative iHOT-33 score (OR, 1.002; 95% CI, 0.98-1.03), primary preoperative diagnosis (OR, 0.86; 95% CI, 0.53-1.40), cam morphology (OR, 1.19; 95% CI, 0.54-2.64), Pincer morphology (OR, 0.50; 95%, CI 0.18-1.38), acetabular labral tears (OR, 1.93; 95% CI, 0.88-4.26), Outerbridge grade 3-4 chondral damage (OR, 0.97; 95% CI, 0.42-2.25), and ligamentum teres pathology (OR, 0.95; 95% CI, 0.35-2.61).
CONCLUSIONS: This study reports a PASS score of 58 for the iHOT-33 at 2 years following hip arthroscopy. The PASS score will assist in assessing response to hip arthroscopy in research and clinical settings. LEVEL OF EVIDENCE: Level II, retrospective prognostic study. Crown
Copyright © 2018. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30301632     DOI: 10.1016/j.arthro.2018.06.049

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  8 in total

Review 1.  Conservative Treatment of a Nondisplaced Intertrochanteric Femur Fracture: A Case Report and Review of the Literature.

Authors:  Jason E Mascoe; Paul K Herickhoff
Journal:  Iowa Orthop J       Date:  2021-12

Review 2.  Arthroscopic hip surgery offers better early patient-reported outcome measures than targeted physiotherapy programs for the treatment of femoroacetabular impingement syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Samer S S Mahmoud; Amir Takla; Denny Meyer; Damian Griffin; John O'Donnell
Journal:  J Hip Preserv Surg       Date:  2022-03-10

3.  How Many Patients Achieve an Acceptable Symptom State After Hip Arthroscopy for Femoroacetabular Impingement Syndrome? A Cross-sectional Study Including PASS Cutoff Values for the HAGOS and iHOT-33.

Authors:  Lasse Ishøi; Kristian Thorborg; Marie G Ørum; Joanne L Kemp; Michael P Reiman; Per Hölmich
Journal:  Orthop J Sports Med       Date:  2021-04-09

4.  Defining the Patient Acceptable Symptom State Using the Forgotten Joint Score 12 After Hip Arthroscopy.

Authors:  Patrick G Robinson; Paul Gaston; Thomas R Williamson; Iain R Murray; Julian F Maempel; Conor S Rankin; Deborah J MacDonald; David F Hamilton
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-08-30

5.  Treatment decisions after interdisciplinary evaluation for nonarthritic hip pain: A randomized controlled trial.

Authors:  Lindsey Brown-Taylor; Marcie Harris-Hayes; Randi Foraker; William Kelton Vasileff; Kathryn Glaws; Stephanie Di Stasi
Journal:  PM R       Date:  2021-08-16       Impact factor: 2.298

6.  Improving function in people with hip-related pain: a systematic review and meta-analysis of physiotherapist-led interventions for hip-related pain.

Authors:  Joanne L Kemp; Andrea B Mosler; Harvi Hart; Mario Bizzini; Steven Chang; Mark J Scholes; Adam I Semciw; Kay M Crossley
Journal:  Br J Sports Med       Date:  2020-05-06       Impact factor: 13.800

7.  Parameters affecting baseline hip function in patients with cam-derived femoroacetabular impingement syndrome: data analysis from the German Cartilage Registry.

Authors:  Sebastian Serong; Moritz Schutzbach; Stefan Fickert; Philipp Niemeyer; Christian Sobau; Gunther Spahn; Wolfgang Zinser; Stefan Landgraeber
Journal:  J Orthop Traumatol       Date:  2021-08-04

8.  Outcome-Affecting Parameters of Hip Arthroscopy for Femoroacetabular Impingement with Concomitant Cartilage Damage-Data Analysis from the German Cartilage Registry.

Authors:  Sebastian Serong; Stefan Fickert; Philipp Niemeyer; Ingo J Banke; Jens Goronzy; Christian Sobau; Wolfgang Zinser; Stefan Landgraeber
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.